Literature DB >> 27246016

[Pathogenesis of psoriasis].

K Schäkel1, M P Schön2, K Ghoreschi3.   

Abstract

Psoriasis is an inflammatory T cell-mediated autoimmune disease of skin and joints that affects 2-4 % of the adult population and 0.1-1 % of children. Genetic susceptibility, environmental triggering factors, and innate immune processes initiate psoriasis pathogenesis that results in an adaptive autoreactive response. The T cell response is orchestrated by CD 8(+) T cells in the epidermis and by CD 4(+) T cells in the dermis that predominantly produce interleukin-17 (IL‑17). Research of the past 15 years unraveled cellular and molecular mechanisms as well as cytokines like TNF-α or IL‑23 that contribute to psoriatic inflammation. This knowledge has been translated into clinical practice and a number of antipsoriatic small molecules and immunobiologics are now available. Here, we discuss the current principles of psoriasis pathogenesis in the context of modern therapies.

Entities:  

Keywords:  Autoimmune diseases; IL‑23; Inflammation; Skin; Th17

Mesh:

Substances:

Year:  2016        PMID: 27246016     DOI: 10.1007/s00105-016-3800-8

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  83 in total

Review 1.  Th17 Cell Pathway in Human Immunity: Lessons from Genetics and Therapeutic Interventions.

Authors:  Dhavalkumar D Patel; Vijay K Kuchroo
Journal:  Immunity       Date:  2015-12-15       Impact factor: 31.745

2.  A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.

Authors:  Kenneth B Gordon; Kristina Callis Duffin; Robert Bissonnette; Jörg C Prinz; Yasmine Wasfi; Shu Li; Yaung-Kaung Shen; Philippe Szapary; Bruce Randazzo; Kristian Reich
Journal:  N Engl J Med       Date:  2015-07-09       Impact factor: 91.245

3.  A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes.

Authors:  K Schäkel; E Mayer; C Federle; M Schmitz; G Riethmüller; E P Rieber
Journal:  Eur J Immunol       Date:  1998-12       Impact factor: 5.532

4.  8-methoxypsoralen plus ultraviolet A therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder.

Authors:  Tej Pratap Singh; Michael P Schön; Katrin Wallbrecht; Kai Michaelis; Beate Rinner; Gerlinde Mayer; Ulrike Schmidbauer; Heimo Strohmaier; Xiao-Jing Wang; Peter Wolf
Journal:  J Immunol       Date:  2010-05-19       Impact factor: 5.422

5.  Cyclosporin A for psoriasis.

Authors:  W Mueller; B Herrmann
Journal:  N Engl J Med       Date:  1979-09-06       Impact factor: 91.245

6.  Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.

Authors:  Peter Schafer
Journal:  Biochem Pharmacol       Date:  2012-01-10       Impact factor: 5.858

Review 7.  Janus kinases in immune cell signaling.

Authors:  Kamran Ghoreschi; Arian Laurence; John J O'Shea
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

8.  IL-4 abrogates T(H)17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells.

Authors:  Emmanuella Guenova; Yuliya Skabytska; Wolfram Hoetzenecker; Günther Weindl; Karin Sauer; Manuela Tham; Kyu-Won Kim; Ji-Hyeon Park; Ji Hae Seo; Desislava Ignatova; Antonio Cozzio; Mitchell P Levesque; Thomas Volz; Martin Köberle; Susanne Kaesler; Peter Thomas; Reinhard Mailhammer; Kamran Ghoreschi; Knut Schäkel; Boyko Amarov; Martin Eichner; Martin Schaller; Rachael A Clark; Martin Röcken; Tilo Biedermann
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-02       Impact factor: 11.205

9.  IL-23 promotes maintenance but not commitment to the Th17 lineage.

Authors:  Gretta L Stritesky; Norman Yeh; Mark H Kaplan
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

Review 10.  From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited.

Authors:  Katia Boniface; Bianca Blom; Yong-Jun Liu; René de Waal Malefyt
Journal:  Immunol Rev       Date:  2008-12       Impact factor: 12.988

View more
  7 in total

1.  [Psoriasis].

Authors:  R Sabat; M P Schön; K Schäkel
Journal:  Hautarzt       Date:  2016-06       Impact factor: 0.751

2.  IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE).

Authors:  Kilian Eyerich; Peter Weisenseel; Andreas Pinter; Knut Schäkel; Khusru Asadullah; Sven Wegner; Ernesto J Muñoz-Elias; Holger Bartz; Friedmann J H Taut; Kristian Reich
Journal:  BMJ Open       Date:  2021-09-13       Impact factor: 3.006

Review 3.  T cell pathology in skin inflammation.

Authors:  Robert Sabat; Kerstin Wolk; Lucie Loyal; Wolf-Dietrich Döcke; Kamran Ghoreschi
Journal:  Semin Immunopathol       Date:  2019-04-26       Impact factor: 9.623

Review 4.  Adaptive and Innate Immunity in Psoriasis and Other Inflammatory Disorders.

Authors:  Michael P Schön
Journal:  Front Immunol       Date:  2019-07-26       Impact factor: 7.561

Review 5.  Transcription Factor Retinoid-Related Orphan Receptor γt: A Promising Target for the Treatment of Psoriasis.

Authors:  Lipeng Tang; Xiaozhi Yang; Yongxin Liang; Hesong Xie; Zhenhua Dai; Guangjuan Zheng
Journal:  Front Immunol       Date:  2018-05-30       Impact factor: 7.561

Review 6.  The Interleukin-23/Interleukin-17 Axis Links Adaptive and Innate Immunity in Psoriasis.

Authors:  Michael P Schön; Luise Erpenbeck
Journal:  Front Immunol       Date:  2018-06-15       Impact factor: 7.561

Review 7.  Interleukin-1 Links Autoimmune and Autoinflammatory Pathophysiology in Mixed-Pattern Psoriasis.

Authors:  Rodolfo Kölliker Frers; Matilde Otero-Losada; Tamara Kobiec; María Inés Herrera; Lucas Udovin; Carlos F Kusnier; Francisco Capani
Journal:  Mediators Inflamm       Date:  2021-10-16       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.